Quellen (Literatur auf Anfrage erhältlich bei Lundbeck):
3 Fachinformation Vyepti®. Swissmedic. Online: www.swissmedicinfo.ch (abgerufen am 06.02.2023).
9 Ashina M et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 2020; 40: 241–254.
10 Lipton RB et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 2020; 94: e1365–1377.
11 Winner PK et al. Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial. JAMA 2021; 325: 2348-2356.
12 Dodick DW et al. Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing. Headache 2020; 60(10): 2220-2231.
3 Fachinformation Vyepti®. Swissmedic. Online: www.swissmedicinfo.ch (abgerufen am 06.02.2023).
9 Ashina M et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 2020; 40: 241–254.
10 Lipton RB et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 2020; 94: e1365–1377.
11 Winner PK et al. Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial. JAMA 2021; 325: 2348-2356.
12 Dodick DW et al. Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing. Headache 2020; 60(10): 2220-2231.